Bio-Techne (TECH) stock: key figures, P/E, revenue and dividend
Health Care · Life Sciences Tools & Services · United States · ISIN US09073M1045
Bio-Techne financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 1.22 bn USD | 1.22 bn USD |
| Gross profit | 790.27 m USD | 799.07 m USD |
| Operating income | 102.26 m USD | 251.89 m USD |
| EBIT | 103.09 m USD | 246.09 m USD |
| Net income | 73.40 m USD | 181.86 m USD |
| Diluted EPS – continuing operations | 0.46 USD | 1.16 USD |
Full history since 1989, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
More stocks
- Biomerieux SA (BIM.PA)
- Sprott Physical Silver (PSLV.TO)
- Pearson PLC (PSON.L)
- ARROW ELECTRONICS, INC. (ARW)
- Mirae Asset Daewoo Securities Co Ltd (006800.KS)
- CP ALL Public Company Limited (CPALL.BK)
- Madison Air Solutions Corporation (MAIR)
- Marks and Spencer Group PLC (MKS.L)
- Klepierre SA (LI.PA)
- American Homes 4 Rent (AMH)
- Cathay Pacific Airways Ltd (293.HK)
- Taisei Corp (1801.T)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.